New Mexico Health Care Authority Pharmacy & Therapeutics/ Drug Utilization Review Board Meeting Minutes

Date & Time	April 13, 2026, 8AM – 12PM MST (scheduled time) Start Time 8:04 a.m.	
Virtual option:	Microsoft Teams **Join:** https://teams.microsoft.com/meet/27052306698947?p=I71oCHbFBlPiwnscGC Meeting ID: 270 523 066 989 47 Passcode: eA6XJ3Zj	
Attendees **The public attendee list is included as Attachment A.** Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, therefore, the accuracy of the attendee list is not assured.	**Committee Board Members**	
	Amy Bachyrycz, Pharm D	Present
	Caroline Bonham, MD	Present
	Stephanie Gehres, MD	Present
	Kate Morton	Present
	Van Roper	Present
	Mary Jo Zuni	Present
	New Mexico Health Care Authority Staff - Present	
	• Cynthia Gustafson, Project Manager • Diana Moya, Pharmacist • Erika Ortega, Certified Pharmacy Technician • Keenan Ryan, Director of Pharmacy, Acting Chief Medical Officer	
	Conduent Staff – Present	
	• Amy Cully, Clinical Pharmacist, Director of DUR, Retro DUR • Lorin Meskin, Manager, Pharmacy Benefits Management • Brad Stevens, Pro DUR edits • Benson Ninan – Pharmacist	
	Prime Therapeutics Staff – Present	
	• Heather Epps, CPHT, Business Analyst Sr. • James Kim, Pharm D. Clinical Account Services • Claudia Soto, AVP Account Management	
	Mercer Staff - Present	
	• Jim Cook, Senior Principal, Specialty Consulting Sector • Leslie Lugo, Pharmacist	

DRAFT

	• Janine Statt, Pharmacist • Lisa Daniels, Pharmacist

Agenda Item	Record	Notes
	OPEN SESSION	
Call to Order and Roll Call	Keenan Ryan, HCA Director of Pharmacy, called the meeting to order at 8:04 AM on April 13, 2026. Keenan took the roll.	A quorum was present.
Approval for Agenda (Attachment A)	Board Member Roper moved to approve the meeting minutes, and Board Member Bonham seconded the motion.	Agenda approved by vote. No questions or concerns were provided.
Approval of Minutes from 1.16.26 meeting (Attachment B)	Board Member Roper moved to approve the meeting minutes, and Board Member Bonham seconded the motion.	Agenda approved by vote. No questions or concerns were provided.
State Updates	Keenan Ryan addressed HCA's switch to new Turquoise Claims with full go live 3/23/26. Telephone number provided for any provider issues. Keenan Ryan discussed Community Pharmacy List (not on agenda) and will send around for vote after the meeting. Keenan Ryan reminded the Committee the PDL will go live on July 1, 2026. This will give space for CMdS go-live and allow MCOs more time to configure their systems. July 1 is the soft launch, medications not denied at pharmacy counter. Anticipated for at least 6 months. Keenan Ryan announced the new state and federal guidance that requires Medicaid enrollment for both billing entity as well as the ordering/rendering provider (ORP). For more information see www.hca.nm.gov/orp/ **Question from Dr. Bachyrycz re rejections. Answer – portal isn't up yet.** Keenan Ryan discussed the open positions on the Board, the Chair and Vice-Chair positions to be	

DRAFT

	voted on at next quarterly meeting. There is a need for a public member of the P&T/DUR Committee.	
NM FFS/MCO Client Counts and Pharmacy	**Lorin Meskin with Conduent leads discussion.** • Enrollment counts for FFS/MCO about 18% FFS and 82% Managed Care • Member Demographics reviewed. Percentage of usage shown in accompanying slides upward trend	No comments or concerns were noted.
a) ProDUR	Brad Stevens leads discussion	
	Discussion of edits - Trending the same as last quarter. Code 4204 edits is 41. Benzo is 4432 at 127, down from 206 last month. Code 4195 at 44. Code 4521 is 1527 due to not putting MO on the claim being submitted.	
b) RetroDUR	Amy Cully leads discussion	
i) Recent Interventions – Summary Report on Polypharmacy with Psychotropic Medications	Amy Cully reviewed intervention for Polypharmacy with Psychotropic Medications (4th Qtr 2025).	Mailed to 157 providers.
ii) Outcome Report for Humira Intervention	Amy Cully reviewed Summary Reports – Humira Intervention Decrease due to providers not using Humira with FDA approval equates to a decrease of $251,322 from the pre-to-post period.	No comments or concerns were noted.
iii) Data Results – Quarterly Reports – Top 25 Drugs by Number of Claims	Amy Cully reviewed the results from Jan-Feb 2026, remains consistent with previous months Amy noted increase in Albuterol and Ibuprofen due to allergies. Diabetes medications or supplies are consistent month to month. Items for cold and flu season increased, including doubling of Tamiflu.	No comments or concerns were noted.
iv) Review Quarterly Reports –	Amy Cully reviewed the report summary for the 10 brand names by number of claims. Top drug for both months continues to be Lantus. Amy then also reviewed the Quarterly reports for top 10 generic drugs per claims.	No comments or concerns were noted.

DRAFT

	Amy then reviewed the Quarterly reports for top 10 therapeutic class by number of claims. Similar to what we saw in Top 25 claims. NSAIDS, intake convulsant, analgesics, antihistamines, antibiotics, and inhaled short-acting beta-adrenergic agents.	
CLOSED SESSION – PDL Class Review 9:00 a.m.		
a) Call to Order and Roll Call	Keenan Ryan, HCA Director of Pharmacy, called the meeting to order at 9:00 am on April 13, 2026. Keenan took the roll. Committee Members present NM HCA staff present Prime Therapeutics staff present	A quorum was present.
a) Review of Drug Classes with Proposed Changes	Keenan Ryan explained that the PDL would start with a small review of classes. And that the intent is to build up the PDL over time. 340B question from Dr. Morton. James Kim reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session. Discuss shortage strategy on next meeting. James Kim presented the financial review of the new drug classes being reviewed for proposed addition: • Androgenic Agents • Antiemetic/Antivertigo Agents • Antimigraine Agents, Other • Antimigraine Agents, Triptans • Bone Resorption Suppression and Related Agents • COPD Agents • Glucocorticoids, Inhaled	

	• Growth Hormones • Hypoglycemics, Insulin Related Agents • Hypoglycemics, SGLT2 • Immumodulators, Asthma • Immunomodulators, Atopic Dermatitis • Lipotropics, Other • Movement Disorders • Multiple Sclerosis Agents • Ophthalmic, Dry Eye Agents • PAH Agents, oral and Inhaled	
OPEN SESSION – Pharmacy and Therapeutics 10:05 a.m.		
Call to Order and Roll Call	Keenan Ryan, HCA Director of Pharmacy, called the meeting to order at 10:00 AM on April 13, 2026. Keenan took the roll. Committee Members present Keenan advised the following outline for the meeting. • Each drug class will be presented at the end of the presentation of the class, we will ask for public comments if you have asked to comment, in which case you have 2 minutes. • There should be no discussion of costs and /or anecdotal activity per our bylaws. • After each of the first 17 drug classes are reviewed and comments made, we will do a class vote. • There will be a large class vote for the drug classes in appendix A.	A quorum was present.
HCA Administrative Updates	Keenan Ryan advised that per P&T/DUR by-laws and best practices, one voting member will be a member of the public.	
DRUG CLASS REVIEW		
Drug Class Review – Clinical Presentations	Keenan Ryan handed the conversation off to Prime Therapeutics, James Kim, PharmD.,	

DRAFT

	Director, Clinical Account Services, to begin discussion around the proposed drug classes to PDL. 1. Androgenic Agents 2. Antiemetic/Antivertigo Agents 3. Antimigraine Agents, Other 4. Antimigraine Agents, Triptans 5. Bone Resorption Suppression and Related Agents 6. COPD Agents 7. Glucocorticoids, Inhaled 8. Growth Hormone 9. Hypoglycemics, Insulin and Related Agents 10. Hypoglycemics, SGLT2 11. Immunomodulators, Asthma 12. Immunomodulators, Atopic Dermatitis 13. Lipotropic, Other 14. Movement Disorders 15. Multiple Sclerosis Agents 16. Ophthalmic, Dry Eye Agents 17. PAH, Oral and Inhaled	
Androgenic Agents - Drug class review presentation by Prime	Testosterone replacement therapies were reviewed, including transdermal gels, topical solutions, and intranasal formulations. These agents are indicated for treatment of adult male hypogonadism.	
Antiemetic/Antivertigo Agents - Drug class review presentation by Prime	James Kim presented on reviewed oral, injectable, rectal, transdermal, and intravenous antiemetic and antivertigo agents, including ondansetron, metoclopramide, promethazine, prochlorperazine, and meclizine.	
Antimigraine Agents - Drug class review presentation by Prime	Calcitonin gene-related peptide (CGRP) monoclonal antibodies and oral CGRP antagonists were reviewed for preventive and acute migraine treatment.	
Antimigraine Agents, Triptans - Drug class review presentation by Prime	Generic triptans were reviewed for acute migraine treatment. All agents within this class demonstrate comparable clinical efficacy.	

DRAFT

Bone Resorption Suppression and Related Agents - Drug class review presentation by Prime	Bisphosphonates and other bone-modifying agents were reviewed for osteoporosis treatment and fracture risk reduction.	
COPD Agents - Drug class review presentation by Prime	Bronchodilators and maintenance therapies were reviewed for chronic obstructive pulmonary disease management and exacerbation reduction.	
Glucocorticoids, Inhaled Agents - Drug class review presentation by Prime	Inhaled corticosteroid products and combination inhalers were reviewed for asthma maintenance and COPD with frequent exacerbations.	
Growth Hormone Agents - Drug class review presentation by Prime	Growth hormone products were reviewed for pediatric and adult growth hormone deficiency and select genetic conditions.	
Hypoglycemics, Insulin and Related Agents - Drug class review presentation by Prime	Basal, rapid-acting, mixed, biosimilar, and inhaled insulin products were reviewed for management of type 1 and type 2 diabetes mellitus.	
Hypoglycemics, SGLT2 Agents - Drug class review presentation by Prime	SGLT2 inhibitors were reviewed for treatment of type 2 diabetes, heart failure, and chronic kidney disease.	
Immunomodulators, Asthma Agents - Drug class review presentation by Prime	Biologic therapies for severe asthma were reviewed for patients uncontrolled on standard inhaled therapy.	
Immunomodulators, Atopic Dermatitis Agents – Drug class review presentation by Prime	Systemic and topical immunomodulators were reviewed for moderate to severe atopic dermatitis.	
Lipotropic, Other Agents – Drug class review presentation by Prime	Oral lipid-lowering therapies and injectable agents were reviewed for treatment of hyperlipidemia and cardiovascular risk reduction.	
Movement Disorders Agents – Drug class review presentation by Prime	Agents for tardive dyskinesia and Huntington's disease-related chorea were reviewed.	
Multiple Sclerosis Agents – Drug class review presentation by Prime	Injectable, oral, and infusion disease modifying therapies were reviewed for relapsing forms of multiple sclerosis.	

DRAFT

Ophthalmics, Dry Eye Agents – Drug class review presentation by Prime	Dry eye therapies were reviewed for chronic ocular surface inflammation.	
PAH Agents, Oral and Inhaled Agents – Drug class review presentation by Prime	Oral and inhaled PAH therapies were reviewed.	
PUBLIC COMMENT		
Drug Classes Public Comment	Telephonic and web comments were called for, and the phone lines were opened. Public comments were provided by: • Sanofi/Regeneron- Dupilumab (Chang) • Galderma - Nemluvio (Nemolizumab) (Carla) • Teva Pharmaceuticals - 1) Austedo XR and 2) Ajovy • Pfizer - Ngenla and Nurtec • Arcutis Biotherapeutics - Zoryve (roflumilast) 0.05% cream and Zoryve (roflumilast) 0.15% cream • Neurocrine BioSciences - Ingrezza (valbenazine) • Novartis - Rhapsido (remibrutinib) and Ofatumumab • Astra Zeneca - 1) Breztri Aerosphere, 2) Airsupra and 3) Fasentra • United Therapeutics – Tyvaso DPI	
Drug Classes Discussion by Board and action by Board to approve (Appendix A)	Board Member Roper moved to accept the class as clinically and therapeutically equivalent presented by Prime and Board Member Bonham seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): Amy Bachyrycz Yes Caroline Bonham Yes Stephanie Gehres Yes Kate Morton Yes	A quorum was present and unanimously approved the classes, no opposed, no abstained.

DRAFT

	Van Roper Yes Mary Jo Zuni Yes	
CLOSING COMMENTS		
Next Steps	Keenan Ryan reviewed next steps • The recommendations will go to Medicaid up to the Director's office to review, sign off, and implement the next steps. • PDL Go-Live is set for July 1, 2026. • The state's website is being rebuilt, and the PDL will be hosted there. • A meeting with the MCOs to review work needed to implement will be forthcoming in the next couple of weeks. • MCO questions should be submitted to Mercer. • Next P&T meeting will be in the next couple of months, and the agenda will be posted to the state website Preferred Drug List – New Mexico Health Care Authority. Virtual participation only.	
Adjournment	Keenan Ryan closed meeting at 10:57 a.m. MST	

DRAFT